Does a body mass index greater than 25 kg/m2 increase maternal and neonatal morbidity? A French historical cohort study - 28/09/17
pages | 8 |
Iconographies | 0 |
Vidéos | 0 |
Autres | 0 |
Abstract |
Objectives |
To evaluate, in a French multicenter cohort, the risk of C-section based on a high pre-pregnancy body mass index (BMI). Secondary objectives were to assess the risk of elective C-section, severe post-partum hemorrhage (>1L), severe perineal tears (3rd and 4th degree) and neonatal complications according to pre-pregnancy BMI.
Study design |
This historical cohort study analyzed records from the French AUDIPOG perinatal database. Inclusion criteria were deliveries≥22 weeks (or with a birth weight≥500g). Women with BMI<18.5kg/m2 (n=31,766) were excluded. After these exclusions, the study sample included 314,851 women between 1999 and 2009. Patients were classified among four BMI subgroups (normal: 18.5–24.9kg/m2, overweight: 25–29.9kg/m2, class I and II obesity: 30–39.9kg/m2 and class III obesity:≥40kg/m2). BMI was calculated using pre-pregnancy self-reported weight. Results were expressed as crude and adjusted relative risks (aRR).
Results |
A C-section occurred in 16.4%, 22.7%, 28.8% and 39.4% of normal BMI, overweight, obese and class III obese women, respectively (P<10−4). aRR of C-section increased with BMI: 1.26 [95%CI: 1.22–1.30] for BMI between 25–29.9kg/m2; 1.39 [95%CI: 1.34–1.45] for BMI between 30–39.9kg/m2 and 1.72 [95%CI: 1.57–1.90] for BMI≥40kg/m2; but not the elective C-section. Neonatal complications were more frequent with increasing maternal BMI (BMI 25–29.9: aRR=1.09 [95%CI: 1.06–1.12]; BMI 30–39.9: aRR=1.20 [95%CI: 1.16–1.25]; BMI≥40: aRR=1.33 [95%CI: 1.21–1.45]).
Conclusion |
Our study confirmed that pre-pregnancy BMI is an important factor to consider because its elevation is associated with adverse obstetrical outcomes, especially cesarean delivery and neonatal complications.
Le texte complet de cet article est disponible en PDF.Keywords : Candida albicans, Resistance, Cross-resistance, Antifungal agents, Burkina Faso
Plan
Vol 46 - N° 7
P. 601-608 - septembre 2017 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?